Pyxis Oncology Prices $110M Public Offering at $2.90, Warrants Could Add $172.6M
PYXS has more than doubled off its 52-week low of $1.03 on light trading volume (0.3× avg).
Summary
Pyxis Oncology priced a public offering of 36 million shares at $2.90 per share, raising $110 million upfront. The deal includes warrants exercisable at $3.50 that could bring in another $172.6 million if fully exercised. This is highly dilutive for a company with a market cap around $242 million. The offering follows a $50 million private placement in July and comes as the company extends its cash runway into Q2 2027. Proceeds will fund the Phase 3 Headliner trial for MICVO in head and neck cancer. The stock is likely to react negatively to the dilution, though the warrant structure ties additional capital to positive clinical data.
Updates
· SEC 424B5 — The final prospectus sets the offering at 36,047,919 shares and pre-funded warrants for 1,883,121 shares, with common warrants for 49,310,352 shares at $3.50, net proceeds of about $102.8 million.
At the time of this announcement, PYXS was trading at $2.63 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $241.9M. The 52-week trading range was $1.03 to $5.55. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.